Imexpharm Corporation (CÔNG TY CP DƯỢC PHẨM IMEXPHARM) is a publicly held joint stock company established in 2001 and headquartered at No. 4, Road 30/4, Ward 1, Cao Lanh City, Dong Thap Province, Vietnam. It is registered under business ID and tax code 1400384433 and listed on the Ho Chi Minh Stock Exchange with the ticker IMP. The company specializes in the manufacture of pharmaceuticals, medicinal chemical and botanical products.

Its leadership team includes Mr. Sung Minwoo (Chairman), Ms. Tran Thi Dao (General Director), and Mr. Huynh Van Nhung (Deputy General Director). The company employs 1,446 staff across its head office and key branches in Ho Chi Minh City, Hanoi, and An Giang.

In 2023, Imexpharm earned USD 81.92 million in revenue and USD 12.31 million in profit. It reported total assets of USD 98.3 million and owner's equity of USD 85.64 million. The company’s strong financial structure, a working capital of over USD 36.94 million, and 34.01% year-on-year profit growth reflect strategic investment and prudent financial management.

Its export readiness and compliance with international standards position it for further regional market penetration.